{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:20:36Z","timestamp":1785446436211,"version":"3.56.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":[".5\/8\/5\/45\/multicentric study\/2019\/ECD-1"],"award-info":[{"award-number":[".5\/8\/5\/45\/multicentric study\/2019\/ECD-1"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/25\/2020\/PHA\/BMS"],"award-info":[{"award-number":["45\/25\/2020\/PHA\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["F.No.5\/8\/5\/45\/multicentric study\/2019\/ECD-1"],"award-info":[{"award-number":["F.No.5\/8\/5\/45\/multicentric study\/2019\/ECD-1"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["32196"],"award-info":[{"award-number":["32196"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.meegid.2026.105883","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:25:52Z","timestamp":1768926352000},"page":"105883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms"],"prefix":"10.1016","volume":"138","author":[{"given":"Levin","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya Shree Dilli","family":"Batcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chaithra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi Sanjay","family":"Parate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S. Keshava","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"Chidananda Sanju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Saravu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surulivelrajan","family":"Mallayasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01978-19","article-title":"Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant south African women with tuberculosis and HIV","volume":"64","author":"Abdelwahab","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.meegid.2026.105883_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4103\/0971-5916.187106","article-title":"N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - a pilot study","volume":"143","author":"Adole","year":"2016","journal-title":"Indian J. Med. Res."},{"issue":"11","key":"10.1016\/j.meegid.2026.105883_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01383-18","article-title":"Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment","volume":"62","author":"Alfarisi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0020","first-page":"125","article-title":"Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India","volume":"11","author":"Anitha","year":"2003","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0025","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bcp.13846","article-title":"Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India","volume":"85","author":"Aruldhas","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.meegid.2026.105883_bb0030","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.meegid.2026.105883_bb0035","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/AAC.01345-13","article-title":"Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus","volume":"57","author":"Babalik","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2026.105883_bb0040","doi-asserted-by":"crossref","unstructured":"Charles B. Population pharmacokinetics: an overview. Aust. Prescr. n.d. 37(6):210\u20133. doi:10.18773\/austprescr.2014.078.","DOI":"10.18773\/austprescr.2014.078"},{"issue":"12","key":"10.1016\/j.meegid.2026.105883_bb0045","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcph.1931","article-title":"Isoniazid population pharmacokinetics and dose recommendation for Korean patients with tuberculosis based on target attainment analysis","volume":"61","author":"Cho","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"34","key":"10.1016\/j.meegid.2026.105883_bb0050","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1002\/anie.202005915","article-title":"Unexpected acetylation of endogenous aliphatic amines by Arylamine N-acetyltransferase NAT2","volume":"59","author":"Conway","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"10","key":"10.1016\/j.meegid.2026.105883_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17512433.2017.1246179","article-title":"The challenges of pharmacokinetic variability of first-line anti-TB drugs","volume":"10","author":"Devaleenal Daniel","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12890-021-01740-y","article-title":"Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age-period-cohort analysis","volume":"21","author":"Dhamnetiya","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"10","key":"10.1016\/j.meegid.2026.105883_bb0070","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00008571-200104000-00004","article-title":"Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms","volume":"11","author":"Fretland","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0080","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bcp.14522","article-title":"Drug exposure of first-line anti-tuberculosis drugs in China: a prospective pharmacological cohort study","volume":"87","author":"Gao","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.meegid.2026.105883_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcph.1993","article-title":"Parametric and nonparametric methods in population pharmacokinetics: experts\u2019 discussion on use, strengths, and limitations","volume":"62","author":"Goutelle","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.meegid.2026.105883_bb0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.1633","article-title":"Parametric approaches in population pharmacokinetics","volume":"62","author":"Guidi","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.meegid.2026.105883_bb0095","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/jgh.12194","article-title":"Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India","volume":"28","author":"Gupta","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.meegid.2026.105883_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283726","article-title":"NAT2 global landscape: genetic diversity and acetylation statuses from a systematic review","volume":"18","author":"Guti\u00e9rrez-Virgen","year":"2023","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.meegid.2026.105883_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/17425250902877698","article-title":"N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine","volume":"5","author":"Hein","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.meegid.2026.105883_bb0110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.5588\/ijtld.16.0048","article-title":"Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India","volume":"20","author":"Hemanth Kumar","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/ijmr.IJMR_2013_15","article-title":"N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis","volume":"145","author":"Hemanth Kumar","year":"2017","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.meegid.2026.105883_bb0120","article-title":"Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA","volume":"2013","author":"Heysell","year":"2013","journal-title":"Tuberc Res. Treat."},{"issue":"45","key":"10.1016\/j.meegid.2026.105883_bb0125","first-page":"6003","article-title":"NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis","volume":"13","author":"Higuchi","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.meegid.2026.105883_bb0130","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.clinthera.2020.09.009","article-title":"A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis","volume":"42","author":"Hong","year":"2020","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.meegid.2026.105883_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00008-18","article-title":"Evaluation of the adequacy of WHO revised dosages of the first-line Antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations","volume":"62","author":"Horita","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.meegid.2026.105883_bb0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5588\/ijtld.18.0433","article-title":"The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis","volume":"23","author":"Huangfu","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"4","key":"10.1016\/j.meegid.2026.105883_bb0145","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s11096-020-01086-1","article-title":"Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis","volume":"42","author":"Huerta-Garc\u00eda","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2026.105883_bb0150","unstructured":"Human NAT2 alleles (haplotypes). Alexandroupolis: Department of Molecular Biology and Genetics, n.d. Democritus University of Thrace. Available from: https:\/\/nat.mbg.duth.gr\/Homepage.htm."},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01736-19","article-title":"Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China","volume":"64","author":"Jing","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2026.105883_bb0160","article-title":"50,000 years of evolutionary history of India: insights from \u223c2,700 Whole Genome Sequences","author":"Kerdoncuff","year":"2024","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/pgs.13.2","article-title":"NAT2 sequence polymorphisms and acetylation profiles in Indians","volume":"14","author":"Khan","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.meegid.2026.105883_bb0170","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FPC.0000000000000232","article-title":"PharmGKB summary: isoniazid pathway, pharmacokinetics","volume":"26","author":"Klein","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-016-2132-z","article-title":"Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus","volume":"73","author":"Kumar","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2026.105883_bb0180","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1038\/hgv.2014.14","article-title":"NAT2 genetic variations among south Indian populations","volume":"1","author":"Lakkakula","year":"2014","journal-title":"Hum. Genome Var."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12863-024-01286-y","article-title":"Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis","volume":"25","author":"Mahajan","year":"2024","journal-title":"BMC Genom Data."},{"issue":"8","key":"10.1016\/j.meegid.2026.105883_bb0190","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2026.105883_bb0195","article-title":"Polymorphism of NAT2, PXR, ABCB1, and GSTT1 genes among tuberculosis patients of North Eastern States of India","author":"Meitei","year":"2021","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.meegid.2026.105883_bb0200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.5588\/ijtld.15.0803","article-title":"Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis","volume":"20","author":"Mota","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"12","key":"10.1016\/j.meegid.2026.105883_bb0205","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1093\/jac\/dkz368","article-title":"Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients","volume":"74","author":"Mtabho","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2026.105883_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijtb.2025.02.018","article-title":"Ecological determinants of paediatric tuberculosis in India","author":"Mukherjee","year":"2025","journal-title":"Indian J. Tuberc."},{"key":"10.1016\/j.meegid.2026.105883_bb0215","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/hgv.2016.14","article-title":"Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients","volume":"3","author":"Mushiroda","year":"2016","journal-title":"Hum. Genome Var."},{"issue":"4","key":"10.1016\/j.meegid.2026.105883_bb0220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/pgs-2018-0166","article-title":"Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in south African patients with recurrent tuberculosis","volume":"20","author":"Naidoo","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0225","doi-asserted-by":"crossref","first-page":"516","DOI":"10.17843\/rpmesp.2020.373.4684","article-title":"Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru","volume":"37","author":"Oscanoa","year":"2020","journal-title":"Rev. Peru Med. Exp. Salud Publica"},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-20","article-title":"Population pharmacokinetic properties of Antituberculosis drugs in Vietnamese children with tuberculous meningitis","volume":"65","author":"Panjasawatwong","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2026.105883_bb0235","article-title":"Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modeling and simulation platform","author":"Rackauckas","year":"2020","journal-title":"BioRxiv"},{"issue":"9","key":"10.1016\/j.meegid.2026.105883_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025801","article-title":"Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation","volume":"6","author":"Rajasekaran","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.meegid.2026.105883_bb0245","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"5\u20136","key":"10.1016\/j.meegid.2026.105883_bb0250","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1445-5994.2003.00390.x","article-title":"Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid","volume":"33","author":"Ray","year":"2003","journal-title":"Intern. Med. J."},{"issue":"12","key":"10.1016\/j.meegid.2026.105883_bb0255","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1111\/j.1572-0241.2002.07109.x","article-title":"Small intestinal glucose absorption and duodenal motility in type 1 diabetes mellitus","volume":"97","author":"Rayner","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.meegid.2026.105883_bb0260","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946202365056","article-title":"Influence of sex on the exposure to isoniazid in patients with pulmonary tuberculosis","volume":"65","author":"Rivera","year":"2023","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"12","key":"10.1016\/j.meegid.2026.105883_bb0265","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1007\/s11033-014-3677-5","article-title":"Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population","volume":"41","author":"Salazar-Gonz\u00e1lez","year":"2014","journal-title":"Mol. Biol. Rep."},{"issue":"5","key":"10.1016\/j.meegid.2026.105883_bb0270","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/cid\/ciy179","article-title":"Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-Coinfected patients with low isoniazid and rifampicin concentrations","volume":"67","author":"Sekaggya-Wiltshire","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.meegid.2026.105883_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02174-18","article-title":"Low Antituberculosis drug concentrations in HIV-tuberculosis-Coinfected adults with low body weight: is it time to update dosing guidelines?","volume":"63","author":"Sekaggya-Wiltshire","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.meegid.2026.105883_bb0280","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1128\/AAC.01244-15","article-title":"Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers","volume":"59","author":"Seng","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.meegid.2026.105883_bb0285","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.meegid.2026.105883_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijid.2022.01.003","article-title":"Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis","volume":"117","author":"Soedarsono","year":"2022","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.meegid.2026.105883_bb0295","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cpt.1806","article-title":"Model-based assessment of variability in isoniazid pharmacokinetics and metabolism in patients co-infected with tuberculosis and HIV: implications for a novel dosing strategy","volume":"108","author":"Sundell","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.meegid.2026.105883_bb0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FPC.0000000000000339","article-title":"NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis","volume":"28","author":"Suvichapanich","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"issue":"10","key":"10.1016\/j.meegid.2026.105883_bb0310","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","article-title":"Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models","volume":"78","author":"Thomas","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.meegid.2026.105883_bb0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17512433.2024.2311314","article-title":"Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients","volume":"17","author":"Thomas","year":"2024","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0320","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2478316","article-title":"Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review","volume":"57","author":"Thomas","year":"2025","journal-title":"Ann. Med."},{"issue":"Supple 1","key":"10.1016\/j.meegid.2026.105883_bb0325","doi-asserted-by":"crossref","DOI":"10.4046\/trd.2020.0068","article-title":"The influence of NAT2 genotypes on isoniazid plasma concentration of pulmonary tuberculosis patients in southern Thailand","volume":"83","author":"Ungcharoen","year":"2020","journal-title":"Tuberc. Respir. Dis. (Seoul)."},{"issue":"1","key":"10.1016\/j.meegid.2026.105883_bb0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in south African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2026.105883_bb0335","author":"World Health Organization"},{"issue":"4","key":"10.1016\/j.meegid.2026.105883_bb0340","article-title":"Association of Nat2 gene polymorphism with Antitubercular drug-induced hepatotoxicity in the eastern Uttar Pradesh population","volume":"11","author":"Yadav","year":"2019","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.meegid.2026.105883_bb0345","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/nmo.12330","article-title":"Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions","volume":"26","author":"Yarandi","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"issue":"18","key":"10.1016\/j.meegid.2026.105883_bb0350","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/pgs-2019-0131","article-title":"NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population","volume":"20","author":"Yuliwulandari","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.meegid.2026.105883_bb0355","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00008571-200411000-00002","article-title":"The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation","volume":"14","author":"Zang","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"8","key":"10.1016\/j.meegid.2026.105883_bb0360","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/carcin\/bgm085","article-title":"Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2","volume":"28","author":"Zang","year":"2007","journal-title":"Carcinogenesis"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134826000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134826000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:56:14Z","timestamp":1778522174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134826000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":72,"alternative-id":["S1567134826000079"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2026.105883","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2026.105883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105883"}}